NCT05346926 (3D-cast) is a NA clinical trial of 3D-printed cast in Radius Fracture Distal, sponsored by Alissa Gubeli.

Who is sponsoring NCT05346926?

NCT05346926 is sponsored by Alissa Gubeli.

What drugs are being tested in NCT05346926?

Interventions in NCT05346926: 3D-printed cast, Conventional cast.

What condition does NCT05346926 study?

NCT05346926 studies Radius Fracture Distal.

Is NCT05346926 still recruiting?

NCT05346926 is currently completed. Last updated 26 April 2022.

Last reviewed 2022-04-26 · How we verify

NCT05346926: 3D-cast

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Overnight and In-house 3D-printed Patient-specific Casts for Non-operative Treatment of Distal Radius Fractures

Completed NA Last updated 26 April 2022

What this trial tests

NA trial testing 3D-printed cast in Radius Fracture Distal in 40 participants. Completed in 31 December 2021.

Timeline

1 March 2020

Primary endpoint
31 December 2021

31 December 2021

Quick facts

Lead sponsor	Alissa Gubeli
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	1 March 2020
Primary completion	31 December 2021
Estimated completion	31 December 2021
Sites	1 location across Switzerland

Drugs / interventions tested

3D-printed cast
Conventional cast

Conditions studied

Radius Fracture Distal — all drugs for Radius Fracture Distal →

Sponsor

Alissa Gubeli

Who can join

18 and older, any sex, with Radius Fracture Distal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this prospective randomized trial is the acquisition and evaluation of data to assess the relevance, feasibility and safety of forearm casts based on 3D-printing technology in the nonoperative treatment of distal radius fractures.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05346926 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alissa Gubeli
Last refreshed: 26 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05346926.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing